MARKET

GILD

GILD

Gilead Sciences Inc
NASDAQ
151.43
-1.08
-0.70%
Opening 15:27 02/09 EST
OPEN
152.42
PREV CLOSE
152.50
HIGH
152.75
LOW
150.20
VOLUME
5.00M
TURNOVER
--
52 WEEK HIGH
153.13
52 WEEK LOW
91.47
MARKET CAP
187.87B
P/E (TTM)
23.53
1D
5D
1M
3M
1Y
5Y
1D
Gilead Q4 preview: Core portfolio, Yeztugo launch keep analysts optimistic ahead of earnings
Seeking Alpha · 3h ago
Robinhood, AppLovin, Rivian and More Stocks With Earnings This Week
Benzinga · 3h ago
Should You Buy Gilead Sciences Before Feb. 10?
The Motley Fool · 5h ago
Exploring Gilead Sciences's Earnings Expectations
Benzinga · 6h ago
Invesco QQQ Trust ETF (QQQ) Daily Update, 2/9/2026
TipRanks · 7h ago
Options Volatility and Implied Earnings Moves This Week, February 10 – February 13, 2026
TipRanks · 8h ago
Weekly Report: what happened at GILD last week (0202-0206)?
Weekly Report · 10h ago
Stocks Set to Open Lower as Bond Yields Climb, Key U.S. Economic Data Awaited
Barchart · 15h ago
More
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.

Webull offers Gilead Sciences Inc stock information, including NASDAQ: GILD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GILD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GILD stock methods without spending real money on the virtual paper trading platform.